A recombinant plasmid containing CpG motifs as a novel vaccine adjuvant for immune protection against herpes simplex virus 2

He, Zhuojing; Xu, Juan; Wei, Tao; Fu, Ting; He, Fang; Hu, Ruxi; Jia, Lan; Hong, Yang

doi:10.3892/mmr.2016.5439

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this DNA vaccine has huge potential, it still needs to overcome a series of limitations and challenges. Low immunogenicity is a potential disadvantage; however, multiple types of adjuvants including cytokines, the granulocyte-macrophage colony-stimulating factor, the CpG oligodeoxynucleotide, etc., have been proven helpful for enhancing the immunogenicity of DNA vaccines [ 41 , 42 , 43 ]. Compared with viral vectors, DNA vaccine delivery systems are safer, but the risk of insertional mutagenesis stills exists [ 44 , 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

Protective Immunity against Chlamydia psittaci Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in BALB/c Mice

Wang

Jin

Jie-wen

et al. 2023

IJMS

View full text Add to dashboard Cite

Chlamydia psittaci (C. psittaci), a zoonotic pathogen, poses a potential threat to public health security and the development of animal husbandry. Vaccine-based preventative measures for infectious diseases have a promising landscape. DNA vaccines, with many advantages, have become one of the dominant candidate strategies in preventing and controlling the chlamydial infection. Our previous study showed that CPSIT_p7 protein is an effective candidate for a vaccine against C. psittaci. Thus, this study evaluated the protective immunity of pcDNA3.1(+)/CPSIT_p7 against C. psittaci infection in BALB/c mice. We found that pcDNA3.1(+)/CPSIT_p7 can induce strong humoral and cellular immune responses. The IFN-γ and IL-6 levels in the infected lungs of mice immunized with pcDNA3.1(+)/CPSIT_p7 reduced substantially. In addition, the pcDNA3.1(+)/CPSIT_p7 vaccine diminished pulmonary pathological lesions and reduced the C. psittaci load in the lungs of infected mice. It is worth noting that pcDNA3.1(+)/CPSIT_p7 suppressed C. psittaci dissemination in BALB/c mice. In a word, these results demonstrate that the pcDNA3.1(+)/CPSIT_p7 DNA vaccine has good immunogenicity and immunity protection effectiveness against C. psittaci infection in BALB/c mice, especially pulmonary infection, and provides essential practical experience and insights for the development of a DNA vaccine against chlamydial infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Protective Immunity against Chlamydia psittaci Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in BALB/c Mice

Wang

Jin

Jie-wen

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Plasmid containing multiple CpG motifs have been reported to induce a Th 1 dominant cytokine profile and enhance antigen specific humoral immune response to viral antigens (Guo et al 2011, Luo et al 2012, He et al 2016. It has been reported that phosphorothioate CpG ODN triggers innate immune activation through the TLR9-mediated signaling pathway (Hemmi et al 2000, Kumagai et al 2008, Lange et al 2018), yet whether CpG motif enriched plasmid also stimulates the TLR9 signaling cascade is currently unknown.…”

Section: Discussionmentioning

confidence: 99%

Polish Journal of Veterinary Sciences

Chen

Xin

et al. 2019

View full text Add to dashboard Cite

Phosphorothioate CpG oligodeoxynucleotides (ODN) are reported to be recognized by the membrane-bound TLR9 and trigger the MyD88-dependent up-regulation of Type I interferons and pro-inflammatory cytokines. Whether plasmids containing multiple CpG motifs stimulate the same signaling pathway is yet to be determined. The present results show that the CpG motifs enrich plasmid pUC18-CpG stimulates RAW 264.7 in vitro, mainly through the TBK1-mediated signaling pathway, causing the up-regulation of IFN-β, and pro-inflammatory cytokines TNF-α and IL-6. When pUC18-CpG is co-administered with the recombinant Echinococcus granulosus antigen, the antigen-specific antibody titers are markedly increased compared to the Quil-A adjuvanted group. Antigen specific cytokine quantification shows that cytokine profiles from the pUC18-CpG adjuvanted-group are switched to a Th1-biased immune response.

show abstract

“…Other studies have also assessed the immunogenicity of DNA vaccines containing chemokine-expressing sequences for HIV-1 immunization [144][145][146]. The CpG oligodeoxynucleotide (ODN) is another common genetic adjuvant used for DNA vaccines [9,147,148]. Preclinical studies have demonstrated that CpG ODN activates TLR9-bearing B cells and plasmacytoid dendritic cells and further support the induction of strong Th1-type responses [149].…”

Section: Techniques To Overcome Immunogenic Issues Of Dna Vaccinesmentioning

confidence: 99%

Engineering DNA vaccines against infectious diseases

et al. 2018

View full text Add to dashboard Cite

Engineering vaccine-based therapeutics for infectious diseases is highly challenging, as trial formulations are often found to be nonspecific, ineffective, thermally or hydrolytically unstable, and/or toxic. Vaccines have greatly improved the therapeutic landscape for treating infectious diseases and have significantly reduced the threat by therapeutic and preventative approaches. Furthermore, the advent of recombinant technologies has greatly facilitated growth within the vaccine realm by mitigating risks such as virulence reversion despite making the production processes more cumbersome. In addition, seroconversion can also be enhanced by recombinant technology through kinetic and nonkinetic approaches, which are discussed herein. Recombinant technologies have greatly improved both amino acid-based vaccines and DNA-based vaccines. A plateau of interest has been reached between 2001 and 2010 for the scientific community with regard to DNA vaccine endeavors. The decrease in interest may likely be attributed to difficulties in improving immunogenic properties associated with DNA vaccines, although there has been research demonstrating improvement and optimization to this end. Despite improvement, to the extent of our knowledge, there are currently no regulatory body-approved DNA vaccines for human use (four vaccines approved for animal use). This article discusses engineering DNA vaccines against infectious diseases while discussing advantages and disadvantages of each, with an emphasis on applications of these DNA vaccines. STATEMENT OF SIGNIFICANCE: This review paper summarizes the state of the engineered/recombinant DNA vaccine field, with a scope entailing "Engineering DNA vaccines against infectious diseases". We endeavor to emphasize recent advances, recapitulating the current state of the field. In addition to discussing DNA therapeutics that have already been clinically translated, this review also examines current research developments, and the challenges thwarting further progression. Our review covers: recombinant DNA-based subunit vaccines; internalization and processing; enhancing immune protection via adjuvants; manufacturing and engineering DNA; the safety, stability and delivery of DNA vaccines or plasmids; controlling gene expression using plasmid engineering and gene circuits; overcoming immunogenic issues; and commercial successes. We hope that this review will inspire further research in DNA vaccine development.

show abstract

A recombinant plasmid containing CpG motifs as a novel vaccine adjuvant for immune protection against herpes simplex virus 2

Cited by 4 publications

References 19 publications

Protective Immunity against Chlamydia psittaci Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in BALB/c Mice

Protective Immunity against Chlamydia psittaci Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in BALB/c Mice

Polish Journal of Veterinary Sciences

Engineering DNA vaccines against infectious diseases

Contact Info

Product

Resources

About